Role of taxanes in pancreatic cancer
- PMID: 22969215
- PMCID: PMC3435767
- DOI: 10.3748/wjg.v18.i33.4457
Role of taxanes in pancreatic cancer
Abstract
Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.
Keywords: ABI-007; Advanced disease; Chemotherapy; Drug combinations; Metastatic disease; Pancreatic cancer; Radiotherapy; Taxanes.
Similar articles
-
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.Anticancer Res. 2010 Jul;30(7):2905-9. Anticancer Res. 2010. PMID: 20683031
-
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.J Chemother. 2008 Aug;20(4):509-12. doi: 10.1179/joc.2008.20.4.509. J Chemother. 2008. PMID: 18676234
-
Taxanes: impact on pancreatic cancer.Anticancer Drugs. 2014 May;25(5):584-92. doi: 10.1097/CAD.0000000000000073. Anticancer Drugs. 2014. PMID: 24463484 Review.
-
Chemotherapy of adenocarcinoma of the pancreas.Semin Oncol. 1996 Apr;23(2):220-8. Semin Oncol. 1996. PMID: 8623058 Review.
-
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.Int J Oncol. 2005 Oct;27(4):1125-30. Int J Oncol. 2005. PMID: 16142331
Cited by
-
Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer.Nanomedicine (Lond). 2024;19(24):1977-1993. doi: 10.1080/17435889.2024.2382076. Epub 2024 Sep 3. Nanomedicine (Lond). 2024. PMID: 39225145
-
Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18. Oncol Lett. 2016. PMID: 28105159 Free PMC article.
-
ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1.Cancers (Basel). 2019 Nov 27;11(12):1881. doi: 10.3390/cancers11121881. Cancers (Basel). 2019. PMID: 31783584 Free PMC article.
-
Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer.Onco Targets Ther. 2014 Feb 4;7:187-92. doi: 10.2147/OTT.S40705. eCollection 2014. Onco Targets Ther. 2014. PMID: 24523592 Free PMC article. Review.
-
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.J Med Chem. 2020 Oct 8;63(19):10855-10878. doi: 10.1021/acs.jmedchem.0c00545. Epub 2020 Sep 18. J Med Chem. 2020. PMID: 32886511 Free PMC article.
References
-
- Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–1057. - PubMed
-
- Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7. - PubMed
-
- Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600. - PubMed
-
- Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413. - PubMed
-
- Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–5518. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical